D. E. Shaw & Co. Inc. increased its holdings in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 256.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 429,887 shares of the company's stock after acquiring an additional 309,239 shares during the quarter. D. E. Shaw & Co. Inc. owned about 0.05% of Dr. Reddy's Laboratories worth $6,788,000 as of its most recent SEC filing.
A number of other large investors have also added to or reduced their stakes in RDY. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its holdings in shares of Dr. Reddy's Laboratories by 400.0% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 400,000 shares of the company's stock worth $6,316,000 after buying an additional 320,000 shares during the period. Cetera Investment Advisers increased its stake in shares of Dr. Reddy's Laboratories by 410.5% in the 4th quarter. Cetera Investment Advisers now owns 20,720 shares of the company's stock valued at $327,000 after purchasing an additional 16,661 shares during the last quarter. Balyasny Asset Management L.P. raised its holdings in shares of Dr. Reddy's Laboratories by 781.7% during the 4th quarter. Balyasny Asset Management L.P. now owns 103,850 shares of the company's stock worth $1,640,000 after buying an additional 92,071 shares in the last quarter. Bellevue Group AG lifted its position in shares of Dr. Reddy's Laboratories by 375.4% during the 4th quarter. Bellevue Group AG now owns 97,900 shares of the company's stock worth $1,546,000 after buying an additional 77,305 shares during the last quarter. Finally, Bank of America Corp DE boosted its stake in Dr. Reddy's Laboratories by 123.1% in the fourth quarter. Bank of America Corp DE now owns 1,916,425 shares of the company's stock valued at $30,260,000 after buying an additional 1,057,584 shares in the last quarter. Institutional investors own 3.85% of the company's stock.
Dr. Reddy's Laboratories Trading Down 0.4%
Shares of RDY traded down $0.07 during mid-day trading on Wednesday, reaching $14.44. 334,861 shares of the company were exchanged, compared to its average volume of 2,066,017. The business has a 50 day simple moving average of $13.50 and a two-hundred day simple moving average of $14.03. Dr. Reddy's Laboratories Limited has a 52 week low of $12.26 and a 52 week high of $16.89. The stock has a market capitalization of $12.05 billion, a PE ratio of 22.99 and a beta of 0.33. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92.
Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last issued its quarterly earnings results on Friday, May 9th. The company reported $0.22 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.20 by $0.02. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. The firm had revenue of $996.17 million for the quarter, compared to the consensus estimate of $83.70 billion. On average, analysts predict that Dr. Reddy's Laboratories Limited will post 0.8 earnings per share for the current fiscal year.
Analyst Ratings Changes
Separately, StockNews.com upgraded shares of Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th.
Check Out Our Latest Stock Analysis on RDY
Dr. Reddy's Laboratories Company Profile
(
Free Report)
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
Further Reading
Before you consider Dr. Reddy's Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.
While Dr. Reddy's Laboratories currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
